CTOs on the Move

Mccrone Group Inc

www.mccrone.com

 
Mccrone Group Inc is a Westmont, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.mccrone.com
  • 850 Pasquinelli Dr
    Westmont, IL USA 60559
  • Phone: 630.887.7100

Executives

Name Title Contact Details

Similar Companies

Horizon Pharma

At Horizon Therapeutics, we believe science and compassion must work together to transform lives. We are driven to deliver innovative medicines to those living with rare, autoimmune and severe inflammatory diseases because we uniquely understand the patient journey. For us, success is measured by the numbers that matter most – the number of lives we touch, the number we change and those we work to help save.

Laboratoires Vivacy

Hyaluronic Acid Experts - Aesthetics Medecine – Dermo Cosmetic - Intimate Care

Telix Pharmaceuticals

Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that address significant unmet medical needs in oncology and rare diseases.

Theseus Pharmaceuticals

Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus` lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).

Ionetix

Ionetix Corporation is a pioneering radiopharmaceutical end to end solutions provider for cardiac PET. Cardiac PET with Ammonia N-13.